The forecast for Peptic Ulcer and Gastro-Oesophageal Reflux Diseases (GORD) medicine sales in Germany shows a declining trend from 2024 to 2028. Starting at $645.1 million in 2024, sales gradually decrease to $568.3 million by 2028. The year-on-year decline indicates persistent reduction in sales, with the average decreasing rate from 2024 to 2028 being substantial. The average annual decrease (CAGR) over this five-year period reflects a steady downtrend influenced by factors such as market saturation and improvements in preventative healthcare measures.
Future trends to watch for include potential impacts of new healthcare policies, advancements in alternative treatments and medications, and the effect of demographic changes such as aging population on medicine demand dynamics in Germany.
